Moderna recently announced that its mRNA therapeutic for heart failure patients undergoing coronary artery bypass grafting (CABG) surgery met its primary endpoint in a Phase 2 study.
The...
Bristol Myers Squibb recently announced that Opdivo plus chemotherapy significantly improved event-free survival (EFS) in patients with resectable stage IB to IIIA non-small cell lung cancer...
Eli Lilly and Company recently announced that Jardiance slowed kidney function decline in adults with heart failure with left ventricular ejection fraction (LVEF) over 40 percent regardless of chronic...
GSK recently announced that its drug, daprodustat, was safe and effective in patients with anemia due to chronic kidney disease (CKD).
The Phase 3 ASCENT trial studied the hypoxia-inducible...
Moderna and Metagenomi recently entered into a strategic research and development collaboration to advance new gene editing systems for in vivo human therapeutic applications.
Under the terms of the...
Gilead and Merck recently announced the start of a Phase 2 clinical study evaluating a combination HIV treatment regimen in adults living with the disease.
The open-label study will evaluate the...
Abbott recently launched a new initiative to increase clinical trial diversity in medical research through training, education, and improved clinical research infrastructure throughout the...
Roche recently launched the AVENIO Tumor Tissue CGP Kit, a genomic profiling kit to allow laboratories to expand their oncology research in-house.
AVENIO Tumor Tissue CGP Kit is a...
Daiichi Sankyo and AstraZeneca recently entered into a second clinical trial collaboration and supply agreement with Merck to evaluate an antibody-drug conjugate with Keytruda in patients with...
Eli Lilly and Company recently announced that tirzepatide elicited superior A1C and body weight reductions from baseline in adults with type 2 diabetes with increased cardiovascular risk.
Data...
Bristol Myers Squibb recently announced interim results from a Phase 3 open-label extension trial, which showed the long-term efficacy and safety profile of Zeposia in patients with relapsing forms of...
FDA recently approved Eli Lilly and Company’s Verzenio to treat adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early breast...
Cerner recently launched a new operating unit, Cerner Enviza, that offers data-driven solutions and research services to clarify multi-dimensional data through real-world evidence and...
Pfizer and BioNTech recently announced that their COVID-19 vaccine booster was 95.6 percent effective in individuals compared to placebo.
The randomized, controlled Phase 3 trial...
GSK recently welcomed the World Health Organization’s (WHO) recommendation for the broader development of GSK’s RTS, S malaria vaccine to reduce childhood illness and deaths from malaria in...
Johnson & Johnson recently submitted data to the FDA to support its COVID-19 vaccine booster shot in adults 18 and older.
The submission includes results from the Phase 3 ENSEMBLE study, which...
Johnson & Johnson recently initiated a Phase 3 clinical trial to study its RSV vaccine's efficacy, safety, and immunogenicity against lower respiratory tract disease (LRTD) in adults.
The...
AstraZeneca recently submitted a request to FDA for an emergency use authorization for its long-acting COVID-19 antibody combination, AZD7442.
AstraZeneca optimized AZD7442 using its YTE half-life...
Regeneron recently announced that its COVID-19 antibody cocktail, REGEN-COV, significantly reduced viral load in patients hospitalized with the coronavirus.
The trial enrolled 1,197 patients to...
Pfizer and BioNTech recently submitted data to FDA from the Phase 2/3 clinical trial of their COVID-19 vaccine in children five to 11 years of age.
Last week, the companies announced that...
